2025 Europe Ai-Based Clinical Trials Revenue Opportunities Report
Description
The 2025 Europe Ai-Based Clinical Trials Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in AI-based clinical trials in Europe are Novartis, AstraZeneca, BenevolentAI, and Exscientia. Novartis, headquartered in Basel, Switzerland, focuses on AI-enabled R&D and data science transformation in medicine, partnering with Microsoft to enhance digital capabilities in clinical trials. AstraZeneca, based in the UK, has launched a digital health unit called Evinova, streamlined clinical trial delivery using AI and digital tools, and collaborates with major CROs and cloud providers like AWS to improve trial efficiency. BenevolentAI in London leverages its AI platform to accelerate drug discovery and development with clinical-stage programs and strong collaborations, including with AstraZeneca. Exscientia from Oxford uses AI to shorten drug development times, having progressed AI-designed candidates into clinical trials rapidly, with partnerships across the pharma sector.
Additional active players include startups like Healx and Genome Biologics focusing on rare diseases and RNA therapies with AI-driven approaches. Larger contract research organizations (CROs) such as IQVIA and ICON also integrate AI tools in clinical trial operations, supporting pharma companies in Europe. These companies collectively lead AI integration in clinical trials, from initial drug discovery to trial conduct, reducing timelines and costs while increasing precision in patient monitoring and data analytics.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in AI-based clinical trials in Europe are Novartis, AstraZeneca, BenevolentAI, and Exscientia. Novartis, headquartered in Basel, Switzerland, focuses on AI-enabled R&D and data science transformation in medicine, partnering with Microsoft to enhance digital capabilities in clinical trials. AstraZeneca, based in the UK, has launched a digital health unit called Evinova, streamlined clinical trial delivery using AI and digital tools, and collaborates with major CROs and cloud providers like AWS to improve trial efficiency. BenevolentAI in London leverages its AI platform to accelerate drug discovery and development with clinical-stage programs and strong collaborations, including with AstraZeneca. Exscientia from Oxford uses AI to shorten drug development times, having progressed AI-designed candidates into clinical trials rapidly, with partnerships across the pharma sector.
Additional active players include startups like Healx and Genome Biologics focusing on rare diseases and RNA therapies with AI-driven approaches. Larger contract research organizations (CROs) such as IQVIA and ICON also integrate AI tools in clinical trial operations, supporting pharma companies in Europe. These companies collectively lead AI integration in clinical trials, from initial drug discovery to trial conduct, reducing timelines and costs while increasing precision in patient monitoring and data analytics.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
